Back Refine search Reset
Please choose a search criteria from below
Filters Clear all
Specialties
Treatments

85 results found in London

Sort by:
Showing 11 - 20 of 85 results

Dr Jonathan Krell is a Consultant Oncologist specialising in breast and gynaecological cancers, with particular interest in cancer genetics and hereditary malignancies, especially with respect of BRCA and other gene mutations. His clinical focus is on the systemic management of patients with gynaecological and breast cancers. 

Dr Krell qualified in medicine at Leeds University Medical School, where he also gained a first class honours degree in Pharmacology. He completed junior doctor positions at St James’ Hospital, Leeds and St Thomas’ Hospitals in London. He then undertook oncology training at Charing Cross and Hammersmith Hospitals.

His PhD work was funded by the Medical Research Council and this investigated the interplay between genetic mutations, DNA damage and the response to cancer therapeutics. Dr Krell is a leading member of the translational research team within the Cancer Research UK and Ovarian Cancer Action centres at Imperial College that aim to overcome resistance to current anti-cancer agents in ovarian and breast cancer.

Dr Krell has published more than 100 peer-reviewed papers in academic journals and he regularly presents on his research at national and international conferences.

 


Diseases, Medical Tests and Treatments
  • Chemotherapy
  • Radiotherapy
  • Genetic Testing
  • Breast Cancer
  • Ovarian Cancer
  • Gynaecological Cancers

 

Read more

Dr Timothy Robert Crook is a Consultant in Medical Oncology who works at The Princess Grace Hospital, The Harley Street Clinic, The Wellington Hospital and LOC.

He specialises in Bladder cancer, breast disease, chemotherapy, kidney cancer, oncology and skin cancer.


Diseases, Medical Tests and Treatments
  • Bladder cancer
  • Breast disease
  • Chemotherapy
  • Kidney cancer
  • Oncology
  • Skin cancer
  • Bladder cancer
  • Breast disease
  • Chemotherapy
  • Kidney cancer
  • Oncology
  • Skin cancer
Read more

Professor Schmid is an internationally renowned breast cancer oncologist. He is the clinical director of the Breast Cancer Centre at St. Bartholomew’s Hospital in London, and Chair in Cancer Medicine at Barts Cancer Institute, Queen Mary University London.

Professor Peter Schmid’s work is devoted to incorporating novel therapies based on an understanding of the biology of cancer with excellent quality of care into the treatment of women with breast cancer. He has an interest in breast cancer from diagnosis throughout treatment to optimal recovery, and also has a particular interest in triple-negative breast cancer, young women with breast cancer, pregnancy-associated breast cancer, and fertility-related issues. Professor Schmid is committed to patient-centered, holistic care, tailoring treatments for individual patients using biology, personal preference, and constant review of outcomes of care. He works in the context of a multidisciplinary team with breast care nurse support for patients. Professor Schmid has a strong interest in patient-doctor communication and ran a training program for oncologists and oncology nurses for many years. Professor Schmid’s research is dedicated to improving the care of women with breast cancer by developing more effective and less toxic treatments.

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

Read more

Martin graduated from the University of Newcastle upon Tyne and gained general medical experience in New Zealand, Australia and the United Kingdom, becoming a member of the Royal College of Physicians (UK) in 2000. Since then he has been working in cancer care, training in Medical Oncology at the Oxford Radcliffe and Royal Marsden NHS Trusts. During this time, he achieved a PhD at the Institute for Cancer Research, London, and was awarded the EORTC-PAMM Young Investigator Award in 2004. He completed his specialist training in Medical Oncology in 2008 and was appointed as a UCL Clinical Senior Lecturer and UCH Consultant in Medical Oncology in 2009. Since then he has been running a research-based practice and has been principal/chief investigator for more than 20 early and late phase clinical trials.

Martin is involved in the management of patients with both lung and head and neck cancers. He is interested in drug development and in using the increasing understanding of cancer biology to design studies that distinguish patient populations most likely to gain benefit from new drugs and new drug combinations. He has a particular interest in cancer biology that leads to the development of both lung and head and neck cancers.


Diseases, Medical Tests and Treatments
  • Chemotherapy
  • Lung and head and neck cancers
  • Drug development 
  • Cancer biology
Read more
Oncology
29 years of experience
Breast Cancer, Clinical Oncology, Colon Cancer + 4more

Dr Cleator is an experienced breast and colorectal oncologist specializing in delivery of chemotherapy, targeted treatments and radiotherapy for early and advanced disease. Her NHS base is at Imperial Healthcare Trust (Charing Cross) and she consultants privately at LOC, Harley Street. She delivers treatment privately within the HCA and London Clinic facilities. 

Her initial medical training was gained at Oxford University. She has an academic background having undertaken a PhD based at the Institute of Cancer Research and Royal Marden Hospitals studying gene profiling as a means of personalizing chemotherapy delivery. She continues to be active in research and education. Particular interests include treatment of breast cancer in young women and pregnancy, neoadjuvant (pre surgical) treatment, personalization of treatment with use of gene assays and radiotherapy for early breast cancer. 

 

 

 

Read more

Dr Constantine Alifrangis is a Consultant Medical Oncologist in London. He specialises in the treatment of urological cancers including prostate, bladder, testicular and penile cancer.

He graduated from Guys’ Kings and St Thomas’ Medical school and was awarded the University Gold Medal for medicine. Following this, he completed his postgraduate medical training in oncology at Imperial College London. He undertook research into advanced prostate cancer at Hammersmith Hospital, and was awarded a Wellcome Trust fellowship to research the link between cancer genetics and the efficacy of novel therapies. He was awarded a PhD by the University of Cambridge in 2014 for this work. He was also awarded the Sylvia Lawler prize by the Oncology section of the Royal Society of Medicine.

In 2016, he was appointed Consultant Medical Oncologist at University College London Hospital and St Bartholomew’s. He is the Lead Oncologist for Testicular Cancer, treating patients with advanced prostate cancer and is part of a specialist team looking after patients with penile cancer.

He is actively involved in research into the genetic basis of cancer and drug resistance, including personalised approaches to cancer treatment. He is also the Lead Investigator for number of clinical studies looking at rarer and understudied cancers. He has presented his research at a number of international conferences and published research in various cancer journals including the Lancet, Journal of Clinical Oncology, and Clinical Cancer Research.


Diseases, Medical Tests and Treatments
  • Chemotherapy 
  • Bladder Cancer
  • Genito-urinary Cancer
  • Penile Cancer
  • Prostate Cancer
  • Testicular Cancer
Read more

Professor Paul Ellis is a Consultant Medical Oncologist based in London, UK. He has a specialist interest in research into novel therapies in breast cancer management was heavily involved in chairing the UK Dept. of Health Advisory committee on the introduction of Herceptin into UK clinical practise, co-authoring the national guidelines of its use.

 

After attaining his Medical Degree from Otago University, New Zealand he then moved to London to complete his fellowship in Medical Oncology and postgraduate research degree at the Royal Marsden Hospital. It was here he submitted his MD thesis on the biological predictors of response to primary chemotherapy. 

 

Professor Paul Ellis continues to take an active leadership role within the UK and European Clinical Trials community. He was the principal investigator and co-chair in the trial management group for the UK National Adjuvant Chemotherapy (TACT) Trial and has been heavily involved on the Steering Committees of numerous other clinical trials of novel anti-cancer therapies including recently being Co-PI on the MARIANNE and KAMILLA trials. 

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

Read more
Oncology
31 years of experience
Clinical Oncology

Dr Beatrice Seddon is consultant on the Sarcoma Unit at University College Hospital, which together with the Bone Tumour Unit at the Royal National Orthopaedic Hospital, comprises the London Bone and Soft Tissue Tumour Service.

Dr Seddon trained in treating sarcomas at the Royal Marsden and Middlesex Hospitals in London, and now specialises exclusively in the treatment of soft tissue and bone sarcomas with chemotherapy and radiotherapy.

She completed her PhD (University of London) at the Institute of Cancer Research in imaging of tumour hypoxia, and currently has a strong interest in clinical trials in sarcoma, acting as principal and chief investigator for a number of national and international trials. She is actively involved in coordinating sarcoma research at a national level as a member of the NCRN Sarcoma Clinical Studies Group, and is also a member of the EORTC Soft Tissue and Bone Sarcoma Group. She regularly teaches and lectures on the management of sarcomas.

 

 


Diseases, Medical Tests and Treatments
  • Chemotherapy
  • Radiotherapy

 

  • Bone Cancer
  • Sarcoma

 

Read more

Professor John Bridgewater is a Consultant Medical Oncologist and Clinical Researcher at the UCL Cancer Institute. He specialises in gastrointestinal oncology, with a particular interest in biliary tract cancers and carcinomas of unknown primary origin.

After studying medicine at Oxford and University College London, he went on to specialise in Medical Oncology at the Middlesex, Mount Vernon and Royal Marsden Hospital. He was awarded a PhD by the Institute of Cancer Research for research into gene therapy. In 1999 he was appointed as a Senior Lecturer in Medical Oncology at UCL.

Professor Bridgewater leads the National Cancer Research Institute subgroup in hepatobiliary malignancy and also has a laboratory programme at the UCL Cancer Institute investigating carcinoma of unknown primary origin. He is also active in trials across the gastrointestinal portfolio and has been the chief investigator on a number of landmark studies into gastrointestinal and biliary tract cancers. As well as his clinical and research work, he also serves on a number of committees including The National Institute for Health and Care Excellence (NICE) and National Cancer Research Institute (NCRI). 


Diseases, Medical Tests and Treatments
  • Chemotherapy 
  • Bilary Cancer 
  • Bowel Cancer 
  • Cancer Unknown Primary
  • Gastro-intestinal Cancers
  • Liver Cancer 

 

Read more
Oncology
19 years of experience
Medical Oncology

Dr Gerlinger is a Consultant Medical Oncologist specializing in the treatment of oesophageal, stomach and bowel cancers. He leads the Translational Oncogenomics Research Team at the Institute of Cancer Research, London. 

He studied Medicine at the University of Munich, at Harvard Medical School, and at Imperial College London and obtained his research MD from the Institute of Immunology at the University in Munich. He trained in General Medicine and Medical Oncology at the University Hospital Zurich, Switzerland, at University College Hospital, The Royal Marsden Hospital and St Bartholomew’s Hospital in London. He undertook post-doctoral research training in cancer immunotherapy in Zurich and in cancer genomics and biomarker discovery at the Cancer Research UK London Research Institute. 

He became a Consultant Medical Oncologist at St Bartholomew’s Hospital in London in 2012. In 2013 he joined The Royal Marsden Hospital as a Consultant in Gastrointestinal Oncology and the Institute of Cancer Research to lead a research group developing new immunotherapies and targeted therapies for drug-resistant cancers. He is developing and leading clinical trials based on research discoveries from his laboratory and other labs worldwide.

Read more